Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)
We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza’s general hospital (north Italy). 25 cancer patients infected by COVID-19 admitted at the Piacenza’s general hospital from 21 February to 18 March 2020. Outcome from the infection were compared wit...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2020-07, Vol.16 (20), p.1425-1432 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1432 |
|---|---|
| container_issue | 20 |
| container_start_page | 1425 |
| container_title | Future oncology (London, England) |
| container_volume | 16 |
| creator | Stroppa, Elisa Maria Toscani, Ilaria Citterio, Chiara Anselmi, Elisa Zaffignani, Elena Codeluppi, Mauro Cavanna, Luigi |
| description | We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza’s general hospital (north Italy).
25 cancer patients infected by COVID-19 admitted at the Piacenza’s general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients.
20 patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%.
Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study. |
| doi_str_mv | 10.2217/fon-2020-0369 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7222528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2403040652</sourcerecordid><originalsourceid>FETCH-LOGICAL-c559t-1f8446d4301b31be327a3b96f2dfb439741018ae5d33b4e1e8e39dc46b0aa8de3</originalsourceid><addsrcrecordid>eNp1kU1rFTEUhoNYbK0u3UrATV1MzceZj2yEcmm1UOhG1yGTObEpc5Nrkqncf2-GW4sWXCUhz3k457yEvOPsXAjef3IxNIIJ1jDZqRfkhPcAzSAZf1nv0Kum6xQck9c53zMGvWzZK3IsBTCpoDshaRNTDObBpyXTyWc0GauPK-oDtSZYTHRnisdQ8jm9oAl3MRUaHS13SJ1PuVDRPifXYkN_YS6YqiYuoaQ9PbsuZt5_fEOOnJkzvn08T8n3q8tvm6_Nze2X683FTWPbVpWGuwGgm6COMko-ohS9kaPqnJjcCFL1wBkfDLaTlCMgxwGlmix0IzNmmFCeks8H724ZtzjZ2lgys94lvzVpr6Px-t-f4O_0j_igeyFEK4YqOHsUpPhzqcPorc8W59kEjEvW6xIZsK4VFf3wDL2PSwp1vEr1EmCQwypsDpRNMeeE7qkZzvSapq5p6jVNvaZZ-fd_T_BE_4mvAuoAuKUsCbOt27eoD69a4a0P-B_5b5guroo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473448388</pqid></control><display><type>article</type><title>Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)</title><source>MEDLINE</source><source>PubMed Central</source><creator>Stroppa, Elisa Maria ; Toscani, Ilaria ; Citterio, Chiara ; Anselmi, Elisa ; Zaffignani, Elena ; Codeluppi, Mauro ; Cavanna, Luigi</creator><creatorcontrib>Stroppa, Elisa Maria ; Toscani, Ilaria ; Citterio, Chiara ; Anselmi, Elisa ; Zaffignani, Elena ; Codeluppi, Mauro ; Cavanna, Luigi</creatorcontrib><description>We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza’s general hospital (north Italy).
25 cancer patients infected by COVID-19 admitted at the Piacenza’s general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients.
20 patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%.
Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2020-0369</identifier><identifier>PMID: 32403946</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Age Factors ; Aged ; Aged, 80 and over ; Antiretroviral drugs ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Azithromycin - therapeutic use ; Betacoronavirus ; cancer patients and COVID-19 ; Cancer therapies ; Ceftriaxone - therapeutic use ; Chronic obstructive pulmonary disease ; cobicistat ; Cobicistat - therapeutic use ; Coronavirus Infections - drug therapy ; Coronavirus Infections - mortality ; Coronaviruses ; COVID-19 ; darunavir ; Darunavir - therapeutic use ; Drug Therapy, Combination ; Female ; HIV Protease Inhibitors - therapeutic use ; Humans ; hydroxychloroquine ; Hydroxychloroquine - therapeutic use ; infection and cancer ; Italy ; lopinavir ; Lopinavir - therapeutic use ; Male ; Methylprednisolone - therapeutic use ; Middle Aged ; Neoplasms - drug therapy ; Neoplasms - mortality ; oncology and coronavirus ; Pandemics ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - mortality ; ritonavir ; Ritonavir - therapeutic use ; SARS-CoV-2</subject><ispartof>Future oncology (London, England), 2020-07, Vol.16 (20), p.1425-1432</ispartof><rights>2020 Luigi Cavanna</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Luigi Cavanna 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c559t-1f8446d4301b31be327a3b96f2dfb439741018ae5d33b4e1e8e39dc46b0aa8de3</citedby><cites>FETCH-LOGICAL-c559t-1f8446d4301b31be327a3b96f2dfb439741018ae5d33b4e1e8e39dc46b0aa8de3</cites><orcidid>0000-0002-0303-3778</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222528/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222528/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32403946$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stroppa, Elisa Maria</creatorcontrib><creatorcontrib>Toscani, Ilaria</creatorcontrib><creatorcontrib>Citterio, Chiara</creatorcontrib><creatorcontrib>Anselmi, Elisa</creatorcontrib><creatorcontrib>Zaffignani, Elena</creatorcontrib><creatorcontrib>Codeluppi, Mauro</creatorcontrib><creatorcontrib>Cavanna, Luigi</creatorcontrib><title>Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza’s general hospital (north Italy).
25 cancer patients infected by COVID-19 admitted at the Piacenza’s general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients.
20 patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%.
Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiretroviral drugs</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Azithromycin - therapeutic use</subject><subject>Betacoronavirus</subject><subject>cancer patients and COVID-19</subject><subject>Cancer therapies</subject><subject>Ceftriaxone - therapeutic use</subject><subject>Chronic obstructive pulmonary disease</subject><subject>cobicistat</subject><subject>Cobicistat - therapeutic use</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - mortality</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>darunavir</subject><subject>Darunavir - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>hydroxychloroquine</subject><subject>Hydroxychloroquine - therapeutic use</subject><subject>infection and cancer</subject><subject>Italy</subject><subject>lopinavir</subject><subject>Lopinavir - therapeutic use</subject><subject>Male</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - mortality</subject><subject>oncology and coronavirus</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - mortality</subject><subject>ritonavir</subject><subject>Ritonavir - therapeutic use</subject><subject>SARS-CoV-2</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kU1rFTEUhoNYbK0u3UrATV1MzceZj2yEcmm1UOhG1yGTObEpc5Nrkqncf2-GW4sWXCUhz3k457yEvOPsXAjef3IxNIIJ1jDZqRfkhPcAzSAZf1nv0Kum6xQck9c53zMGvWzZK3IsBTCpoDshaRNTDObBpyXTyWc0GauPK-oDtSZYTHRnisdQ8jm9oAl3MRUaHS13SJ1PuVDRPifXYkN_YS6YqiYuoaQ9PbsuZt5_fEOOnJkzvn08T8n3q8tvm6_Nze2X683FTWPbVpWGuwGgm6COMko-ohS9kaPqnJjcCFL1wBkfDLaTlCMgxwGlmix0IzNmmFCeks8H724ZtzjZ2lgys94lvzVpr6Px-t-f4O_0j_igeyFEK4YqOHsUpPhzqcPorc8W59kEjEvW6xIZsK4VFf3wDL2PSwp1vEr1EmCQwypsDpRNMeeE7qkZzvSapq5p6jVNvaZZ-fd_T_BE_4mvAuoAuKUsCbOt27eoD69a4a0P-B_5b5guroo</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Stroppa, Elisa Maria</creator><creator>Toscani, Ilaria</creator><creator>Citterio, Chiara</creator><creator>Anselmi, Elisa</creator><creator>Zaffignani, Elena</creator><creator>Codeluppi, Mauro</creator><creator>Cavanna, Luigi</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0303-3778</orcidid></search><sort><creationdate>20200701</creationdate><title>Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)</title><author>Stroppa, Elisa Maria ; Toscani, Ilaria ; Citterio, Chiara ; Anselmi, Elisa ; Zaffignani, Elena ; Codeluppi, Mauro ; Cavanna, Luigi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c559t-1f8446d4301b31be327a3b96f2dfb439741018ae5d33b4e1e8e39dc46b0aa8de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiretroviral drugs</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Azithromycin - therapeutic use</topic><topic>Betacoronavirus</topic><topic>cancer patients and COVID-19</topic><topic>Cancer therapies</topic><topic>Ceftriaxone - therapeutic use</topic><topic>Chronic obstructive pulmonary disease</topic><topic>cobicistat</topic><topic>Cobicistat - therapeutic use</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - mortality</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>darunavir</topic><topic>Darunavir - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>hydroxychloroquine</topic><topic>Hydroxychloroquine - therapeutic use</topic><topic>infection and cancer</topic><topic>Italy</topic><topic>lopinavir</topic><topic>Lopinavir - therapeutic use</topic><topic>Male</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - mortality</topic><topic>oncology and coronavirus</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - mortality</topic><topic>ritonavir</topic><topic>Ritonavir - therapeutic use</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stroppa, Elisa Maria</creatorcontrib><creatorcontrib>Toscani, Ilaria</creatorcontrib><creatorcontrib>Citterio, Chiara</creatorcontrib><creatorcontrib>Anselmi, Elisa</creatorcontrib><creatorcontrib>Zaffignani, Elena</creatorcontrib><creatorcontrib>Codeluppi, Mauro</creatorcontrib><creatorcontrib>Cavanna, Luigi</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stroppa, Elisa Maria</au><au>Toscani, Ilaria</au><au>Citterio, Chiara</au><au>Anselmi, Elisa</au><au>Zaffignani, Elena</au><au>Codeluppi, Mauro</au><au>Cavanna, Luigi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>16</volume><issue>20</issue><spage>1425</spage><epage>1432</epage><pages>1425-1432</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza’s general hospital (north Italy).
25 cancer patients infected by COVID-19 admitted at the Piacenza’s general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients.
20 patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%.
Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>32403946</pmid><doi>10.2217/fon-2020-0369</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-0303-3778</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2020-07, Vol.16 (20), p.1425-1432 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7222528 |
| source | MEDLINE; PubMed Central |
| subjects | Age Factors Aged Aged, 80 and over Antiretroviral drugs Antiviral Agents - therapeutic use Antiviral drugs Azithromycin - therapeutic use Betacoronavirus cancer patients and COVID-19 Cancer therapies Ceftriaxone - therapeutic use Chronic obstructive pulmonary disease cobicistat Cobicistat - therapeutic use Coronavirus Infections - drug therapy Coronavirus Infections - mortality Coronaviruses COVID-19 darunavir Darunavir - therapeutic use Drug Therapy, Combination Female HIV Protease Inhibitors - therapeutic use Humans hydroxychloroquine Hydroxychloroquine - therapeutic use infection and cancer Italy lopinavir Lopinavir - therapeutic use Male Methylprednisolone - therapeutic use Middle Aged Neoplasms - drug therapy Neoplasms - mortality oncology and coronavirus Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - mortality ritonavir Ritonavir - therapeutic use SARS-CoV-2 |
| title | Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A06%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Coronavirus%20disease-2019%20in%20cancer%20patients.%20A%20report%20of%20the%20first%2025%20cancer%20patients%20in%20a%20western%20country%20(Italy)&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Stroppa,%20Elisa%20Maria&rft.date=2020-07-01&rft.volume=16&rft.issue=20&rft.spage=1425&rft.epage=1432&rft.pages=1425-1432&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2020-0369&rft_dat=%3Cproquest_pubme%3E2403040652%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473448388&rft_id=info:pmid/32403946&rfr_iscdi=true |